Brief: Sorrento Therapeutics Says China's National Medical Products Administration Clears Lee's Pharmaceutical To Conduct Phase III Trial Of Socazolimab
08/03/2021 03:35
March 7 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* LEE’S PHARMACEUTICAL ANNOUNCES ITS ANTI-PD-L1 ANTIBODY
SOCAZOLIMAB, LICENSED FROM SORRENTO THERAPEUTICS, RECEIVES
CLEARANCE TO START PHASE 3 TRIAL AS A FIRST-LINE TREATMENT OF
EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
* CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION CLEARS
LEE'S
PHARM TO CONDUCT A PHASE III TRIAL OF SOCAZOLIMAB
* SHANGHAI CHEST HOSPITAL IS EXPECTED TO INITIATE PATIENT
RECRUITMENT IN Q2
* LEE'S PHARM EXPECTS TO FILE NEW DRUG APPLICATION FOR
SOCAZOLIMAB
IN RECURRENT OR METASTATIC CERVICAL CANCER IN Q2
Source text for Eikon: ID:nGNX8vTCRp
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals